To include your compound in the COVID-19 Resource Center, submit it here.

Contrave naltrexone SR/bupropion SR regulatory update

FDA approved a resubmitted NDA from Orexigen for Contrave naltrexone/bupropion as an adjunct to diet and exercise for chronic weight management in adults with obesity or who are overweight with co-morbidities. The agency is requiring an additional postapproval cardiovascular outcomes trial with a pre-specified goal to

Read the full 469 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE